ClinicalTrials.Veeva

Menu

A Study of Observation and Follow-up in People With Basal Cell Carcinoma

Memorial Sloan Kettering Cancer Center (MSK) logo

Memorial Sloan Kettering Cancer Center (MSK)

Status

Enrolling

Conditions

Basal Cell Carcinoma

Treatments

Diagnostic Test: Total Skin Examinations
Diagnostic Test: Dermtech tape-stripping
Diagnostic Test: Reflectance confocal microscopy (RCM)
Diagnostic Test: Digital Dermoscopy
Diagnostic Test: Optical coherence tomography (OCT)

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

The purpose of this study is to find out more about how Basal Cell Carcimonas/BCCs grow and to learn more effective ways to monitor and treat these common cancers. This study will not provide any type of treatment for the participants' cancer; it is a 3-year observational study to monitor participants' cancer.

Enrollment

33 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients 18 years of age or older
  • Diagnosed with at least 1 BCC based on clinical, dermoscopy, RCM and OCT
  • Patients with BCCs that have a diameter smaller or equal to 1.5cm, allowing for 0.5cm growth before reaching the cutoff for stage 2 BCC, which would require removal of the BCC.
  • Patients with BCCs that have a depth smaller or equal to 0.6mm, to allow for tumor growth of 0.2mm before reaching the depth limitation of OCT imaging (0.8mm)
  • Treatment naiive lesions
  • Ability to sign informed consent

Exclusion criteria

  • Immunosuppressed patients, such as those with a primary immunodeficiency caused by a genetic abnormality and a secondary immunodeficiency caused by AIDS, cancer, chemotherapy and other immunomodulating drugs, solid organ transplant recipitents, CLL, aspelenia, and pregnancy).
  • Patients with cancer genetic syndromes that increase risk of BCC (such as basal cell nevus syndrome, xeroderma pigmentosum, epidermolysis bulosa, oculocutaneous albinism, bazex-dupre-christol syndrome, rothmund-thomson syndrome, and epidermodysplasia verruciformis).
  • Patients with BCCs that are clinically suspected as high risk histopathologic subtypes, i.e. indented or sclerotic lesions that are suspected as morpheaform or infiltrative BCCs.
  • Patients with BCCs that have a diameter larger than 1.5cm\
  • Patients with BCCs that have a depth greater than 0.6mm
  • Patients with BCCs in high risk locations, i.e. "H" area of the face. (is located in the mid-face at the site of the embryologic fusion plates and is generally believed to be associated with more aggressive skin cancers).
  • Patients with BCCs on locations that may compromise an organ function should the tumor enlarge (for example, eyelid).
  • Tumor located on a site that precludes attachment of the RCM device or inability to tolerate imaging procedure (i.e. remain relatively still for multiple short durations of 3- 4 minutes over a total time of 20-30 minutes)
  • Lesions that previously received therapeutic intervention
  • Inability to give informed consent

Trial design

33 participants in 1 patient group

Participant with Basal Cell Carcinoma/BCC
Description:
Participants have been diagnosed with at least 1 Basal Cell Carcinoma/BCC based on clinical, dermoscopy, RCM (reflectance confocal microscopy) and OCT (optical coherence tomography)
Treatment:
Diagnostic Test: Dermtech tape-stripping
Diagnostic Test: Optical coherence tomography (OCT)
Diagnostic Test: Digital Dermoscopy
Diagnostic Test: Reflectance confocal microscopy (RCM)
Diagnostic Test: Total Skin Examinations

Trial contacts and locations

1

Loading...

Central trial contact

Allan Halpern, MD; Ashfaq Marghoob, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems